IPOs & Funding vs FDA Actions
Side-by-side coverage analysis for IPOs & Funding and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
IPOs & Funding
Biotech IPOs, venture funding
- Stories
- 7
- Avg Impact
- 5.6/10
- Dominant Tone
- Neutral
- Latest
- Mar 24, 2026
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 20
- Avg Impact
- 7/10
- Dominant Tone
- Bullish
- Latest
- 2d ago
Recent Headlines
IPOs & Funding
- Sai Parenterals Debuts ₹409-Crore IPO as Pharma Injectables Gain Momentum
- Sunway Healthcare Defies Geopolitical Headwinds in Strong Market Debut
- GSP Crop Science Launches Rs 400 Crore IPO Amid Muted Market Sentiment
- Medtronic’s MiniMed Prices IPO at $20 Per Share, Raising $560 Million
- Medtronic Unit MiniMed Raises $560M in IPO Amid Cautious Market Pricing
- Sunway Healthcare Targets $736M IPO to Fuel Regional Expansion
- Gaudium IVF IPO Enters Final Day with 3x Subscription and Positive GMP
FDA Actions
- Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
- Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
- Cannabis Rescheduling Could Unlock $2.2B for Biotech & Pharma R&D, Challenger Says
- Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
- Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
- HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
- AIIMS Recruits 460+ Researchers, Supercharging India’s Biomedical Pipeline
- First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status
- Roundup Ruling: 7-2 SCOTUS Verdict Reduces Bayer's Liability by Billions
- $6.5B Fraud Sweep Nabs Genetic Testing Scams: Biotech’s Compliance Wake-Up Call